FindTrial
Sign In

TORIPALIMAB INJECTION(JS001 )

DRUG6 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., First Affiliated Hospital of Zhejiang University, Peking University First Hospital, Hebei Medical University Fourth Hospital, Fudan University

Conditions

Biliary Tract Cancer (BTC)Esophageal Squamous Cell Carcinoma Stage IIEsophageal Squamous Cell Carcinoma Stage IIIHR-positive,HER2-negative Breast CancerHepatocellular CarcinomaImmunotherapyNon-small Cell Lung CancerRadiation Therapy

Phase 2

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection
Active, not recruitingNCT03859128
Shanghai Junshi Bioscience Co., Ltd.Hepatocellular Carcinoma
Start: 2019-03-05End: 2027-12-31Updated: 2026-08-10
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
RecruitingNCT06705127
First Affiliated Hospital of Zhejiang UniversityHR-positive,HER2-negative Breast Cancer
Start: 2024-07-01End: 2028-07-01Target: 30Updated: 2024-11-26
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
RecruitingNCT06889649
Peking University First HospitalImmunotherapy, Radiation Therapy, Renal Cancer Metastatic +1
Start: 2019-01-01End: 2028-02-20Target: 30Updated: 2025-03-21
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
Not yet recruitingNCT06903871
Hebei Medical University Fourth HospitalEsophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Start: 2025-04-01End: 2030-03-01Target: 190Updated: 2025-04-01
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Not yet recruitingNCT06919848
Fudan UniversityBiliary Tract Cancer (BTC)
Start: 2025-05-01End: 2027-05-01Target: 74Updated: 2025-04-09

Phase 3

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
CompletedNCT03924050
Shanghai Junshi Bioscience Co., Ltd.Non-small Cell Lung Cancer
Start: 2019-05-06End: 2025-02-24Updated: 2026-08-06

Related Papers

Efficacy and safety of SABR/partial‑SABR combined with axitinib and toripalimab in recurrent or metastatic renal cell carcinoma: Preliminary results from a prospective phase 2 trial
Oncology Letters2025-06-02
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.
2021-10-1578 citations
A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.
Journal of Clinical Oncology2020-05-2014 citations